Studying Fentanyl in Patients With Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Brain Cancer, Blood Cancer, Lymphoma, Hematology, Leukemia |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/30/2013 |
| Start Date: | October 2007 |
Pharmacokinetics of Continuous Infusion Fentanyl in Cancer Patients
RATIONALE: Studying blood samples from cancer patients undergoing pain treatment in the
laboratory may help doctors learn more about how pain drugs work in the body. It may also
help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at fentanyl in patients with cancer.
OBJECTIVES:
- To describe the pharmacokinetics of prolonged intravenous infusions of fentanyl citrate
in adult patients with cancer.
OUTLINE: Patients undergo blood sample collection before and after discontinuation of
fentanyl citrate therapy (10 days total). Pharmacokinetic analysis is performed on the
samples.
DISEASE CHARACTERISTICS:
- Diagnosis of cancer
- Inpatient at the Johns Hopkins Hospital Cancer Center undergoing pain treatment with
continuous infusion fentanyl citrate for ≥ 5 days
PATIENT CHARACTERISTICS:
- Willing to change to an alternative opioid
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- At least 72 hours since transdermal fentanyl citrate administration
- At least 12 hours since transmucosal fentanyl citrate administration
- No known requirement for continued opioid therapy with any fentanyl citrate products
after discontinuation of fentanyl citrate therapy
We found this trial at
1
site
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The name Johns Hopkins has become synonymous...
Click here to add this to my saved trials
